Oscar Health's Q4 Wake‑Up Call: A 95% MLR Spike—and Why 2026 Is the Real Battleground

Before the market opened on Feb. 10, $Oscar Health (OSCR.US)$ released its Q4 and full‑year results. For Oscar, this quarter marks a transition point—from a narrative driven largely by policy tailwinds to one increasingly judged on fundamentals. After several quarters in which membership growth pulled revenue higher, Q4 showed clear signs of slowing momentum on the membership side, intensifying profitability pressure, and greater policy uncertainty. That said, the company’s more upbeat 2026 outlook helped push the stock up more than 10%.

Key figures

– Revenue: $2.805B, up 17.3% YoY, but below consensus of $3.11B

– Q4 net loss: $353M; EPS: -$1.24, worse than consensus -$0.89

– The key driver of the wider loss was a sharp jump in Medical Loss Ratio (MLR)—from 88.5% in Q3 to 95.4% in Q4

– Full‑year revenue: $11.701B, below the company’s $12.0–$12.2B guidance

– 2026 guidance (positive): revenue rising to $18.7–$19.0B, MLR improving to 82.4%–83.4%, and operating profit of $250M–$450M

The core issue: MLR spiked—SG&A improvement can’t save the P&L

Revenue growth did continue: +17.3% YoY shows the company’s scale is still expanding, but the pace is meaningfully below the earlier quarters’ run‑rate.

Cash‑flow resilience improved as well: free cash flow margin rose to 23.6%, suggesting progress in expense control and cash management.

The real problem in Q4 was profitability: MLR surged to ~95.4%, up 6.9 percentage points from Q3’s 88.5%. While industrywide factors like an aging population and higher utilization have put upward pressure on MLRs (large insurers such as $UnitedHealth (UNH.US)$ have faced similar trends), Oscar’s outsized spike is the biggest red flag. It suggests that under a combination of higher member utilization and risk‑adjustment transfers, Oscar’s current pricing and actuarial assumptions didn’t sufficiently cover claims costs—directly compressing gross margin.

SG&A trends were directionally positive: Oscar reported an SG&A ratio of ~18.2%, improving year over year. But it remains a mid‑range level given ongoing growth and marketing needs—and it simply can’t offset an MLR shock of this magnitude.

In other words, Oscar isn’t “failing to sell.” The issue is that in this round of ACA market risk and cost inflation, underwriting profitability effectively “blew up” in Q4. SG&A is coming down, but claims costs rose far more than the market expected, dragging the earnings model lower.

Membership: marginal slowdown—and even a sequential decline

Oscar noted that 2025 full‑year membership reached an all‑time high. But from a public‑markets perspective, what matters more is the incremental trend:

– Individual & Small Group members (Q4): 2.042M

– Individual & Small Group members (Q3): 2.112M

What that implies:

– Growth isn’t linear. When ACA pricing rises, subsidies become uncertain, and consumers revisit enrollment decisions, membership can slow—or even fall.

– For 2026, Oscar must prove it can grow membership while improving risk quality. Otherwise, the bigger it gets, the faster it can lose money.

Strategy & outlook: why 2026 guidance can “reset the narrative”

Despite the weak Q4 print, Oscar issued a strong 2026 outlook—one of the main reasons the stock reacted positively pre‑market.

2026 guidance highlights

– Revenue: $18.7B–$19.0B (well above Wall Street expectations)

– Operating profit: $250M–$450M (the first clear annual profitability framework)

– Full‑year MLR: 82.4%–83.4%

Management’s levers are straightforward: a more “affordable” product mix, technology (including “agentic AI features”) to improve experience and operating efficiency, and tighter cost discipline.

The company also added a $475M, 3‑year revolving credit facility in early February, emphasizing “optimizing capital structure and increasing flexibility to support growth.”

The key to focus on inside that guidance is MLR. If Oscar can really bring MLR back to ~82–83% in 2026, it implies structural improvement in at least one of the following: pricing, risk selection, medical management, or the fit between risk adjustment and the member base. Otherwise, it’s hard to credibly move from ~95% to the low‑80s.

The revenue jump looks great—but it’s also the hardest part to execute. Moving from $11.7B in 2025 to ~$18.7B in 2026 essentially requires Oscar to break through simultaneously on ACA individual market share, product mix, and channel efficiency. Policy shifts and intensifying competition could make that path much bumpier.

What to track next

Over the next few quarters, the question is no longer simply “can Oscar keep growing?”—it’s whether Oscar can prove its growth is profitable and sustainable:

1. Individual & Small Group membership: does growth resume, with stable retention?

2. Quarterly MLR: does it steadily retreat from Q4’s peak and converge toward the 2026 target range?

3. Risk adjustment / morbidity volatility: does it continue to materially erode the income statement (the core variable in 2025’s “reset year”)?

4. SG&A ratio: can it keep trending down toward the 15.8%–16.3% range guided for 2026?

5. Operating profit trajectory: do we see sustainable quarter‑to‑quarter improvement rather than one‑off swings?

97K Views